Searchable abstracts of presentations at key conferences in endocrinology

ea0083erco5 | Endocrine-related Cancer | EYES2022

PD-1, PD-L1 and CTLA-4 immune checkpoint expression – Is there a prognostic impact on adrenocortical carcinoma?

L Landwehr , I Sbiera , B Altieri , H Remde , S Kircher , S. Sbiera , M. Kroiss , M. Fassnacht

Adrenocortical carcinoma (ACC) is a very severe endocrine malignancy with poor prognosis. While cancer immunotherapies have revolutionized the treatment of several cancer entities, the results of initial studies of different immune checkpoint inhibitors in ACC were heterogeneous and clinically substantial responses were observed only in a subset of patients. Expression of immune checkpoint molecules - programmed cell death 1 (PD-1), its ligand PD-L1 and cytotoxic T Lymphocytes...

ea0083erco4 | Endocrine-related Cancer | EYES2022

Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma (ACC)

O Kimpel , P Schindler , L Schmidt-Pennington , B Altieri , F Megerle , R Steenaard , J Pittaway , M Quinkler , K Mai , M. Kroiss , B Polat , M. Fassnacht

Background: The ESE-ENSAT guidelines emphasize the role of local therapies and suggest radiotherapy (RT) as an individualized treatment in patients with advanced ACC. However, the evidence for this recommendation is very low.Objectives: The aim of this study was to retrospectively investigate the efficacy and tolerance of RT in advanced ACC.Methods: We screened all patients in five European reference centers for ACC since 2000 for ...